Peptides derived from the SARS-CoV-2 receptor binding motif bind to ACE2 but do not block ACE2-mediated host cell entry or pro-inflammatory cytokine induction.
SARS-CoV-2 viral attachment and entry into host cells is mediated by a direct interaction between viral spike glycoproteins and membrane bound angiotensin-converting enzyme 2 (ACE2). The receptor binding motif (RBM), located within the S1 subunit of the spike protein, incorporates the majority of kn...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2021-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0260283 |
| _version_ | 1819283945183772672 |
|---|---|
| author | Amit Mahindra Gonzalo Tejeda Mario Rossi Omar Janha Imogen Herbert Caroline Morris Danielle C Morgan Wendy Beattie Augusto C Montezano Brian Hudson Andrew B Tobin David Bhella Rhian M Touyz Andrew G Jamieson George S Baillie Connor M Blair |
| author_facet | Amit Mahindra Gonzalo Tejeda Mario Rossi Omar Janha Imogen Herbert Caroline Morris Danielle C Morgan Wendy Beattie Augusto C Montezano Brian Hudson Andrew B Tobin David Bhella Rhian M Touyz Andrew G Jamieson George S Baillie Connor M Blair |
| author_sort | Amit Mahindra |
| collection | DOAJ |
| description | SARS-CoV-2 viral attachment and entry into host cells is mediated by a direct interaction between viral spike glycoproteins and membrane bound angiotensin-converting enzyme 2 (ACE2). The receptor binding motif (RBM), located within the S1 subunit of the spike protein, incorporates the majority of known ACE2 contact residues responsible for high affinity binding and associated virulence. Observation of existing crystal structures of the SARS-CoV-2 receptor binding domain (SRBD)-ACE2 interface, combined with peptide array screening, allowed us to define a series of linear native RBM-derived peptides that were selected as potential antiviral decoy sequences with the aim of directly binding ACE2 and attenuating viral cell entry. RBM1 (16mer): S443KVGGNYNYLYRLFRK458, RBM2A (25mer): E484GFNCYFPLQSYGFQPTNGVGYQPY508, RBM2B (20mer): F456NCYFPLQSYGFQPTNGVGY505 and RBM2A-Sc (25mer): NYGLQGSPFGYQETPYPFCNFVQYG. Data from fluorescence polarisation experiments suggested direct binding between RBM peptides and ACE2, with binding affinities ranging from the high nM to low μM range (Kd = 0.207-1.206 μM). However, the RBM peptides demonstrated only modest effects in preventing SRBD internalisation and showed no antiviral activity in a spike protein trimer neutralisation assay. The RBM peptides also failed to suppress S1-protein mediated inflammation in an endogenously expressing ACE2 human cell line. We conclude that linear native RBM-derived peptides are unable to outcompete viral spike protein for binding to ACE2 and therefore represent a suboptimal approach to inhibiting SARS-CoV-2 viral cell entry. These findings reinforce the notion that larger biologics (such as soluble ACE2, 'miniproteins', nanobodies and antibodies) are likely better suited as SARS-CoV-2 cell-entry inhibitors than short-sequence linear peptides. |
| first_indexed | 2024-12-24T01:39:32Z |
| format | Article |
| id | doaj.art-bd3f0fee6eca437982991ad72b197890 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-24T01:39:32Z |
| publishDate | 2021-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-bd3f0fee6eca437982991ad72b1978902022-12-21T17:22:05ZengPublic Library of Science (PLoS)PLoS ONE1932-62032021-01-011611e026028310.1371/journal.pone.0260283Peptides derived from the SARS-CoV-2 receptor binding motif bind to ACE2 but do not block ACE2-mediated host cell entry or pro-inflammatory cytokine induction.Amit MahindraGonzalo TejedaMario RossiOmar JanhaImogen HerbertCaroline MorrisDanielle C MorganWendy BeattieAugusto C MontezanoBrian HudsonAndrew B TobinDavid BhellaRhian M TouyzAndrew G JamiesonGeorge S BaillieConnor M BlairSARS-CoV-2 viral attachment and entry into host cells is mediated by a direct interaction between viral spike glycoproteins and membrane bound angiotensin-converting enzyme 2 (ACE2). The receptor binding motif (RBM), located within the S1 subunit of the spike protein, incorporates the majority of known ACE2 contact residues responsible for high affinity binding and associated virulence. Observation of existing crystal structures of the SARS-CoV-2 receptor binding domain (SRBD)-ACE2 interface, combined with peptide array screening, allowed us to define a series of linear native RBM-derived peptides that were selected as potential antiviral decoy sequences with the aim of directly binding ACE2 and attenuating viral cell entry. RBM1 (16mer): S443KVGGNYNYLYRLFRK458, RBM2A (25mer): E484GFNCYFPLQSYGFQPTNGVGYQPY508, RBM2B (20mer): F456NCYFPLQSYGFQPTNGVGY505 and RBM2A-Sc (25mer): NYGLQGSPFGYQETPYPFCNFVQYG. Data from fluorescence polarisation experiments suggested direct binding between RBM peptides and ACE2, with binding affinities ranging from the high nM to low μM range (Kd = 0.207-1.206 μM). However, the RBM peptides demonstrated only modest effects in preventing SRBD internalisation and showed no antiviral activity in a spike protein trimer neutralisation assay. The RBM peptides also failed to suppress S1-protein mediated inflammation in an endogenously expressing ACE2 human cell line. We conclude that linear native RBM-derived peptides are unable to outcompete viral spike protein for binding to ACE2 and therefore represent a suboptimal approach to inhibiting SARS-CoV-2 viral cell entry. These findings reinforce the notion that larger biologics (such as soluble ACE2, 'miniproteins', nanobodies and antibodies) are likely better suited as SARS-CoV-2 cell-entry inhibitors than short-sequence linear peptides.https://doi.org/10.1371/journal.pone.0260283 |
| spellingShingle | Amit Mahindra Gonzalo Tejeda Mario Rossi Omar Janha Imogen Herbert Caroline Morris Danielle C Morgan Wendy Beattie Augusto C Montezano Brian Hudson Andrew B Tobin David Bhella Rhian M Touyz Andrew G Jamieson George S Baillie Connor M Blair Peptides derived from the SARS-CoV-2 receptor binding motif bind to ACE2 but do not block ACE2-mediated host cell entry or pro-inflammatory cytokine induction. PLoS ONE |
| title | Peptides derived from the SARS-CoV-2 receptor binding motif bind to ACE2 but do not block ACE2-mediated host cell entry or pro-inflammatory cytokine induction. |
| title_full | Peptides derived from the SARS-CoV-2 receptor binding motif bind to ACE2 but do not block ACE2-mediated host cell entry or pro-inflammatory cytokine induction. |
| title_fullStr | Peptides derived from the SARS-CoV-2 receptor binding motif bind to ACE2 but do not block ACE2-mediated host cell entry or pro-inflammatory cytokine induction. |
| title_full_unstemmed | Peptides derived from the SARS-CoV-2 receptor binding motif bind to ACE2 but do not block ACE2-mediated host cell entry or pro-inflammatory cytokine induction. |
| title_short | Peptides derived from the SARS-CoV-2 receptor binding motif bind to ACE2 but do not block ACE2-mediated host cell entry or pro-inflammatory cytokine induction. |
| title_sort | peptides derived from the sars cov 2 receptor binding motif bind to ace2 but do not block ace2 mediated host cell entry or pro inflammatory cytokine induction |
| url | https://doi.org/10.1371/journal.pone.0260283 |
| work_keys_str_mv | AT amitmahindra peptidesderivedfromthesarscov2receptorbindingmotifbindtoace2butdonotblockace2mediatedhostcellentryorproinflammatorycytokineinduction AT gonzalotejeda peptidesderivedfromthesarscov2receptorbindingmotifbindtoace2butdonotblockace2mediatedhostcellentryorproinflammatorycytokineinduction AT mariorossi peptidesderivedfromthesarscov2receptorbindingmotifbindtoace2butdonotblockace2mediatedhostcellentryorproinflammatorycytokineinduction AT omarjanha peptidesderivedfromthesarscov2receptorbindingmotifbindtoace2butdonotblockace2mediatedhostcellentryorproinflammatorycytokineinduction AT imogenherbert peptidesderivedfromthesarscov2receptorbindingmotifbindtoace2butdonotblockace2mediatedhostcellentryorproinflammatorycytokineinduction AT carolinemorris peptidesderivedfromthesarscov2receptorbindingmotifbindtoace2butdonotblockace2mediatedhostcellentryorproinflammatorycytokineinduction AT daniellecmorgan peptidesderivedfromthesarscov2receptorbindingmotifbindtoace2butdonotblockace2mediatedhostcellentryorproinflammatorycytokineinduction AT wendybeattie peptidesderivedfromthesarscov2receptorbindingmotifbindtoace2butdonotblockace2mediatedhostcellentryorproinflammatorycytokineinduction AT augustocmontezano peptidesderivedfromthesarscov2receptorbindingmotifbindtoace2butdonotblockace2mediatedhostcellentryorproinflammatorycytokineinduction AT brianhudson peptidesderivedfromthesarscov2receptorbindingmotifbindtoace2butdonotblockace2mediatedhostcellentryorproinflammatorycytokineinduction AT andrewbtobin peptidesderivedfromthesarscov2receptorbindingmotifbindtoace2butdonotblockace2mediatedhostcellentryorproinflammatorycytokineinduction AT davidbhella peptidesderivedfromthesarscov2receptorbindingmotifbindtoace2butdonotblockace2mediatedhostcellentryorproinflammatorycytokineinduction AT rhianmtouyz peptidesderivedfromthesarscov2receptorbindingmotifbindtoace2butdonotblockace2mediatedhostcellentryorproinflammatorycytokineinduction AT andrewgjamieson peptidesderivedfromthesarscov2receptorbindingmotifbindtoace2butdonotblockace2mediatedhostcellentryorproinflammatorycytokineinduction AT georgesbaillie peptidesderivedfromthesarscov2receptorbindingmotifbindtoace2butdonotblockace2mediatedhostcellentryorproinflammatorycytokineinduction AT connormblair peptidesderivedfromthesarscov2receptorbindingmotifbindtoace2butdonotblockace2mediatedhostcellentryorproinflammatorycytokineinduction |